EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

SPAN ‐C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma

Joseph Chan iD, Andrew Kneebone iD, Gabrielle Metz iD, Jeremy Booth, Meegan Shepherd iD, Carol Kwong, Chris Brown, Ian Norton, Stephen Clarke, Connie Diakos, Nick Pavlakis, Anubhav Mittal und 2 weitere

Journal of Medical Imaging and Radiation Oncology · 2025

DOI: 10.1111/1754-9485.13874 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2025. Verfasst von Joseph Chan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Radiosurgery, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Varian Medical Systems.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The role of stereotactic body radiotherapy (SBRT) remains unclear in the setting of pancreatic ductal adenocarcinoma (PDAC). This study aims to investigate the safety, feasibility and benefits of SBRT for PDAC in a clinical trial setting.

Methods

SPAN‐C was a single centre, single‐arm, phase II clinical trial. Patients with locally advanced, borderline resectable, and metastatic PDAC suitable for high dose radiation were enrolled. Fiducial marker placement was mandated. Following induction chemotherapy, patients were treated with 40‐45Gy in 5 fractions of external beam radiotherapy. Freedom from local failure at 12 months was the primary endpoint. Secondary endpoints included disease recurrence endpoints, acute and late toxicity, surgical outcomes, and palliative endpoints.

Results

Thirty patients were enrolled. Median follow up of alive patients was 5 years (min 31 months). Twenty‐six completed treatment as per protocol. Nine patients (34.6%) underwent a resection, 5 of whom had a R0 resection and 2 had a complete pathologic response. The 12‐month freedom from local failure was 100% for the resected subgroup and 76.5% for the unresected subgroup. Seven patients (26.9%) had local recurrences, with 5 of these in the unresected group (29.4%). Median OS was 37.9 months for the resected subgroup and 10.7 months for the unresected subgroup. Three patients had grade 3 acute toxicity, and no patients had late high‐grade toxicity.

Conclusions

SBRT was safe and feasible with high rates of local control at 12 months and low rates of toxicity. It appears a valid alternative to chemo‐irradiation in both the pre‐operative and inoperable setting. Trial Registration ClinicalTrials.gov identifier: NCT03505229

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryCarcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansMaleFemaleAgedMiddle AgedAged, 80 and overTreatment OutcomeFeasibility StudiesAdultNeoplasm Recurrence, Local

Stichwörter der Autor:innen

adenocarcinomaductalpancreaticradiotherapystereotactic

Autor:innen und Institutionen

  • Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Kolling Institute of Medical Research, The Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.
  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Gastroenterology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Joseph Chan, Andrew Kneebone, Gabrielle Metz, Meegan Shepherd, George Hruby

Förderung

  • Varian Medical Systems

Zitieren

APA

Chan, J., Kneebone, A., Metz, G., Booth, J., Shepherd, M., Kwong, C., Brown, C., Norton, I., Clarke, S., Diakos, C., Pavlakis, N., Mittal, A., Samra, J., & Hruby, G. (2025). SPAN ‐C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.13874

Vancouver

Chan J, Kneebone A, Metz G, Booth J, Shepherd M, Kwong C, et al. SPAN ‐C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma. Journal of Medical Imaging and Radiation Oncology. 2025. doi:10.1111/1754-9485.13874

BibTeX
@article{Chan2025,
  author = {Chan, Joseph and Kneebone, Andrew and Metz, Gabrielle and Booth, Jeremy and Shepherd, Meegan and Kwong, Carol and Brown, Chris and Norton, Ian and Clarke, Stephen and Diakos, Connie and Pavlakis, Nick and Mittal, Anubhav and Samra, Jaswinder and Hruby, George},
  title = {SPAN ‐C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma},
  journal = {Journal of Medical Imaging and Radiation Oncology},
  year = {2025},
  doi = {10.1111/1754-9485.13874}
}
Kostenlos starten →